Hansa Biopharma AB's market cap is currently kr3.99B. The company's EPS TTM is kr-2.53; its P/E ratio is ―; Hansa Biopharma AB is scheduled to report earnings on July 17, 2025, and the estimated EPS forecast is kr-1.50. See an overview of income statement, balance sheet, and cash flow financials.
